Martin Tenlen was appointed as the general manager of the Nordics region for CSL Behring, the world’s fifth-largest biotech company, at the start of 2019. He highlights his priorities for leading the local affiliate, improving access to new treatments, leveraging Sweden’s innovation-friendly ecosystem through collaboration and strengthening the company’s leading position in the blood plasma market in the Nordics.
The responsibility for driving an innovative environment lies with all stakeholders, so I encourage my peers to collaborate as, in the end, more patients will benefit from this mutual approach
